RUBIN PAUL D
Chief Medical Officer
RUBIN PAUL D has filed 6 SEC Form 4 filings (16 transaction rows) across 1 company, with disclosures dating back to 2025. 6 of those filings fall inside the rolling window. Most recent filing: Apr 3, 2026.
On the most recent filing, RUBIN PAUL D is listed as Chief Medical Officer at BioAge Labs, Inc. Inside the rolling window, RUBIN PAUL D reported no open-market purchases and 6 open-market sales totaling $1.5M in BIOA. The largest disclosed transaction in the window is a sale of 68,897 BIOA shares on Dec 4, 2025, worth $702K.
Companies traded
Other insiders at BIOA
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$1.5M
reported sales (SEC code S)
Companies
1
in the rolling window
| Source | |||||||
|---|---|---|---|---|---|---|---|
| BIOA | Chief Medical Officer | Sale | 8,820 | $157K | Apr 3 | SEC ↗ | |
| BIOA | Chief Medical Officer | Sale | 7,433 | $151K | Mar 3 | SEC ↗ | |
| BIOA | Chief Medical Officer | Sale | 7,433 | $139K | Feb 3 | SEC ↗ | |
| BIOA | Chief Medical Officer | Sale | 7,433 | $95K | Jan 6 | SEC ↗ | |
| BIOA | Chief Medical Officer | Sale | 18,000 | $216K | Dec 11 | SEC ↗ | |
| BIOA | Chief Medical Officer | Sale | 68,897 | $702K | Dec 5 | SEC ↗ |
Frequently asked questions
How many SEC Form 4 filings has RUBIN PAUL D made?
RUBIN PAUL D has filed 6 SEC Form 4 filings (16 transaction rows) across 1 company since 2025.
Which companies does RUBIN PAUL D trade?
RUBIN PAUL D has filed SEC Form 4 disclosures for 1 company, including BIOA.
When was RUBIN PAUL D's most recent SEC Form 4 filing?
RUBIN PAUL D's most recent SEC Form 4 filing on Tracefour is dated Apr 3, 2026.
What is RUBIN PAUL D's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, RUBIN PAUL D is listed as Chief Medical Officer.
What is RUBIN PAUL D's total buy and sell value in the current window?
Inside the rolling retention window, RUBIN PAUL D bought $0 and sold $1.5M based on SEC Form 4 filings.
What was RUBIN PAUL D's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 68,897 BIOA shares on 2025-12-04, worth $702K, per SEC Form 4 filings.